Inventor

MICHAEL HEARTLEIN

Inventor

US

Overview

2021–2026

Patent span

Chemistry

Primary field (CPC C)

Patents· 73 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C12Nprimary

C12NMicroorganisms or enzymes20%

A61KPreparations for medical, dental or toiletry purposes20%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations16%

C12YEnzymes13%

C07KPeptides8%

C07HSugars6%

C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture4%

C07CAcyclic or carbocyclic compounds3%

C07DHeterocyclic compounds3%

C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms2%

PatentTitleYear

12,594,245Dry powder formulations for messenger RNA2026 12,594,295CFTR mRNA compositions and related methods and uses2026 12,577,554Methods for purification of messenger RNA2026 12,577,600Modification of RNA-related enzymes for enhanced production2026 12,569,572Messenger RNA therapy for the treatment of Friedreich's ataxia2026 12,564,645Methods for treatment of methylmalonic acidemia2026 12,552,858Methods and compositions for delivering mRNA coded antibodies2026 12,533,402MRNA therapy for argininosuccinate synthetase deficiency2026 12,509,666MRNA therapy for phenylketonuria2025 12,459,885Ionizable cationic lipids2025 12,453,739Synergistic enhancement of the delivery of nucleic acids via blended formulations2025 12,421,538Quantitative assessment for cap efficiency of messenger RNA2025 12,410,422Methods for purification of messenger RNA2025 12,377,053Cationic polymers2025 12,370,238Composition and methods for treatment of primary ciliary dyskinesia2025 12,370,262Messenger RNA vaccines and uses thereof2025 12,331,005Ionizable cationic lipids2025 12,280,147PEG lipidoid compounds2025 12,280,117Lipid nanoparticle formulations for delivery of MRNA2025 12,268,754Composition and methods for treatment of ornithine transcarbamylase deficiency2025 12,247,046Ribonucleic acids with 4'-thio-modified nucleotides and related methods2025 12,240,824Vitamin cationic lipids2025 12,234,446Methods for purification of messenger RNA2025 12,201,677Messenger RNA therapy for the treatment of ornithine transcarbamylase deficiency2025 12,195,505Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR2025 12,144,871Stable compositions of MRNA-loaded lipid nanoparticles and processes of making2024 12,121,592Lipid nanoparticle compositions and methods for mRNA delivery2024 12,102,720Cleavable lipids2024 12,084,702Methods for purification of messenger RNA2024 12,084,711Quantitative assessment for cap efficiency of messenger RNA2024 12,076,439Thioester cationic lipids2024 12,064,515Process of preparing mRNA-loaded lipid nanoparticles2024 12,060,381Methods for purification of messenger RNA2024 12,016,954CNS delivery of mRNA and uses thereof2024 11,999,675Ionizable cationic lipids2024 11,998,601Messenger RNA therapy for treatment of articular disease2024 11,975,110Cationic polymers2024 11,976,272Methods for purification of messenger RNA2024 11,964,051Ribose cationic lipids2024 11,951,181Lipid nanoparticle compositions and methods for mRNA delivery2024 11,951,180Lipid nanoparticle compositions and methods for MRNA delivery2024 11,951,179Lipid nanoparticle compositions and methods for MRNA delivery2024 11,920,182Quantitative assessment for cap efficiency of messenger RNA2024 11,890,377Lipid formulations for delivery of messenger RNA2024 11,884,692Methods for purification of messenger RNA2024 11,820,977Methods for purification of messenger RNA2023 11,730,825Lipid nanoparticle compositions and methods for mRNA delivery2023 11,712,463MRNA therapy for pompe disease2023 11,692,189Methods for purification of messenger RNA2023 11,560,562Large-scale synthesis of messenger RNA2023 11,559,561Composition and methods for treatment of primary ciliary dyskinesia2023 11,547,764Lipid nanoparticle compositions and methods for MRNA delivery2023 11,547,666Cationic lipids comprising a steroidal moiety2023 11,530,298Poly(phosphoesters) for delivery of nucleic acids2022 11,510,937CFTR MRNA compositions and related methods and uses2022 11,497,716Lipid-derived neutral nanoparticles2022 11,447,520Ribonucleic acids with 4'-thio-modified nucleotides and related methods2022 11,433,144Biodegradable lipids for delivery of nucleic acids2022 11,427,535Polyanionic delivery of nucleic acids2022 11,400,109Subcutaneous delivery of messenger RNA2022 11,377,642mRNA therapy for phenylketonuria2022 11,365,437Quantitative assessment for cap efficiency of messenger RNA2022 11,357,726Process of preparing mRNA-loaded lipid nanoparticles2022 11,338,044Lipid nanoparticle compositions and methods for mRNA delivery2022 11,291,734Lipid nanoparticle compositions and methods for mRNA delivery2022 11,253,605Codon-optimized CFTR MRNA2022 11,254,936Nuclease resistant polynucleotides and uses thereof2022 11,234,936Cleavable lipids2022 11,224,642MRNA therapy for argininosuccinate synthetase deficiency2022 11,185,595Lipid nanoparticle compositions and methods for mRNA delivery2021 11,174,500Methods for purification of messenger RNA2021 11,173,190Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR2021 11,135,274MRNA for use in treatment of human genetic diseases2021

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2021–2026Patents assigned to TRANSLATE BIO INC (73)· patent assignee history

2021–2026Based in US· patent location history

2022–2026Patents assigned to ETHRIS GMBH (2)· patent assignee history

2024Patents assigned to MASSACHUSETTS INST TECHNOLOGY (1)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
TRANSLATE BIO INC	73	2021–2026
ETHRIS GMBH	2	2022–2026
MASSACHUSETTS INST TECHNOLOGY	1	2024

Locations

Location	Patents	Span
US	73	2021–2026